Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

It Is Better To Be In The Hospital For Treating Bulimia Nervosa?
A German study published in the current issue of Psychotherapy and Psychosomatics addresses the differences between inpatient versus day clinic treatment of bulimia nervosa.
generic viagra online
Resolvyx Initiates Phase I Clinical Trial Of Novel Resolvin, RX-10001, For Asthma And Inflammatory Diseases
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating an oral resolvin therapeutic, RX-10001, in a Phase I clinical trial in healthy volunteers. RX-10001 is a synthetic form of RvE1, a naturally occurring resolvin, which in animal studies has been shown to activate the body"s own off-switch mechanisms for inflammation and to promote healing for normal tissue function. In preclinical testing, RX-10001 and analogs have shown high potency across a range of inflammatory disease models, including asthma, colitis, rheumatoid arthritis, and atherosclerosis.
News of the day
H1N1 Spread Continues Worldwide; First Death In Asia Confirmed
The H1N1 (swine flu) virus has now infected more than 52,000 people, leaving 231 dead, the WHO said Monday, AFP/Washington Post reports. "Swine flu has now been reported in 100 countries and territories, and figures yet to be incorporated into the U.N. health agency"s official figures indicate an even higher toll," AFP/Washington Post writes, adding, "The WHO said, however, that its figures could not be considered reliable because some countries were no longer keeping total figures while other poor countries did not have the means to reliably detect cases." Since Friday, the number of cases has grown by more than 7,873 cases and 51 deaths, "highlighting the steady spread of the virus," the newspaper writes (AFP/Washington Post, 6/23).
Health Insurance

Cougar Biotechnology Announces Successful Completion Of Johnson & Johnson's Initial Tender Offer And Commencement Of Subsequent Offering Period

Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced today that the initial offering period of Johnson & Johnson"s (NYSE: JNJ) tender offer for all the outstanding shares of Cougar common stock expired at midnight (Eastern time) on July 2, 2009. The offer was conducted through a wholly-owned subsidiary of Johnson & Johnson named Kite Merger Sub, Inc. The depositary for the tender offer has advised Cougar that, as of the expiration of the initial offering period, a total of approximately 17,742,030 shares of Cougar common stock were validly tendered and not withdrawn, representing approximately 84.4% of Cougar common stock that is outstanding. All shares that were validly tendered and not properly withdrawn during the offering period have been accepted for payment. In addition, the depositary has received commitments to tender approximately 2,001,065 additional shares under the guaranteed delivery procedures described in the offer. Johnson & Johnson has advised Cougar that it is commencing through Kite Merger Sub, Inc., a subsequent offering period of its tender offer to acquire all remaining outstanding shares of Cougar common stock. This subsequent tender offering period will expire at 5:00 p.m. (Eastern time) on Thursday July 9, 2009, unless extended. Any shares validly tendered during this subsequent offering period will be accepted immediately for payment, and tendering stockholders will thereafter promptly be paid $43.00 in cash for each share of Cougar common stock tendered, without interest and less any required withholding taxes. This is the same amount per share that was offered and paid in the initial offering period. Shares tendered during this subsequent offering period cannot be delivered by the guaranteed deliver procedure and may not be withdrawn. In addition, shares validly tendered during the initial offering period may not be withdrawn during the subsequent offering period. Following the expiration of the subsequent offering period, Johnson & Johnson has advised Cougar that it intends to acquire any remaining shares of Cougar common stock through what is known as a "short-form" merger," that is, without a vote or meeting of the remaining stockholders of Cougar. Cougar Biotechnology, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009